| Imagery Source: Wikimedia Commons / Jakednb |
| Information Source: Boston Scientific Corporation |
| Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 per cent on a reported basis, 19.4 per cent on an operational basis, and 15.3 per cent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted EPS of $0.75 for the period, compared to $0.63 a year ago. |
| "We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we shared at our recent Investor Day meeting, we are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities." |
| Third quarter financial results and recent developments: |
- Reported net sales of $5.065 billion, representing an increase of 20.3 pper centon a reported basis, compared to the company's guidance range of 17 to 19 per cent; 19.4per centt on an operational basis; and 15.3 per cent on an organic basis, compared to the company's guidance range of 12 to 14per centt, all compared to the prior year period.
|
- Reported GAAP net income attributable to Boston Scientific common stockholders of $0.51 per share, compared to the company's guidance range of $0.44 to $0.46 per share, and achieved adjusted EPS of $0.75 per share, compared to the guidance range of $0.70 to $0.72 per share.
|
- Achieved the following net sales growth in each reportable segment, compared to the prior year period:
|
-
- MedSurg: 16.per cent reported, 15.6 per cent operational, and 7.per cent organic
|
-
- Cardiovascular: 22.4 per cent reported, 21.5 per cent operational and 19.4 per cent organic
|
- Achieved the following net sales growth/(declines) in each region, compared to the prior year period:
|
-
- United States (U.S.): 27.0 per cent reported and operational
|
-
- Europe, Middle East and Africa (EMEA): 2.6 per cent reported and 2.0 operational
|
-
-
- In the second quarter of 2025, management decided to discontinue worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter.
|
-
- Asia-Pacific (APAC): 17.1 per cent reported and 16.9 per cent operational
|
-
- Latin America and Canada (LACA): 10.4 per cent reported and 9.6 per cent operational
|
-
- Emerging Markets4: 11.8 per cent reported and 11.5 per cent operational
|
- Announced Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for expanded labelling of the FARAPULSE™ Pulsed Field Ablation (PFA) System to include treatment of drug-refractory, symptomatic, persistent atrial fibrillation (AF).
|
- Commenced enrollment in the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT™ Drug-Coated Balloon (DCB) in patients with previously untreated coronary lesions, compared to standard of care percutaneous coronary intervention (PCI) treatment with drug-eluting stents and/or balloon angioplasty.
|
- Published in JAMA Neurology, outcomes from the five-year INTREPID study demonstrate sustained benefits of deep brain stimulation in people with moderate to advanced Parkinson's disease, including improved motor function and quality of life.
|
- Completed asset acquisition with Elutia, Inc. to acquire the antibiotic-eluting EluPro™ BioEnvelope and the CanGaroo® Envelope, designed to prevent certain post-operative complications for devices such as pacemakers and defibrillators.
|
- Announced agreement to acquire Nalu Medical, Inc., developer of the Nalu Neuromodulation System, which is designed to use peripheral nerve stimulation to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin — subject to customary closing conditions.
|
| 1. Operational net sales growth excludes the impact of foreign currency fluctuations. |
| 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. |
| 3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. |
| 4. Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. |
| For the full document, click the link below |
| Boston Scientific Corporation |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
